Citations (87)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (19)
Allan W. Cripps, Temitope Folaranmi, Kelly D. Johnson, Luwy Musey, Michael S. Niederman & Ulrike K. Buchwald. (2021) Immunogenicity following revaccination or sequential vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in older adults and those at increased risk of pneumococcal disease: a review of the literature. Expert Review of Vaccines 20:3, pages 257-267.
Read now
Read now
Michael S. Niederman, Temitope Folaranmi, Ulrike K. Buchwald, Luwy Musey, Allan W. Cripps & Kelly D. Johnson. (2021) Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence. Expert Review of Vaccines 20:3, pages 243-256.
Read now
Read now
Yutong Jiang, Xi Zhang, Qing Lv, Jun Qi, Xinghua Guo, Qiujing Wei, Zetao Liao, Zhiming Lin & Jieruo Gu. (2019) Knowledge, attitude, and practice regarding infection and vaccination in patients with rheumatic diseases in China. Human Vaccines & Immunotherapeutics 15:5, pages 1100-1105.
Read now
Read now
Helen L. Stacey, Jeffrey Rosen, James T. Peterson, Angela Williams-Diaz, Vanita Gakhar, Tina M. Sterling, Camilo J. Acosta, Katrina M. Nolan, Jianing Li, Alison Pedley, Patrice Benner, Chitrananda Abeygunawardana, Michael Kosinski, William J. Smith, Hari Pujar & Luwy K. Musey. (2019) Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults. Human Vaccines & Immunotherapeutics 15:3, pages 530-539.
Read now
Read now
Ger T Rijkers, Laura IE Yousif, Simone MC Spoorenberg & Frans J van Overveld. (2018) Triptych of the Hermit Saints: pneumococcal polysaccharide vaccines for the elderly. Risk Management and Healthcare Policy 11, pages 55-65.
Read now
Read now
Salim Parker, Anwar Ahmed Hoosen, Charles Feldman, Amgad Gamil, Jerusha Naidoo & Shameema Khan. (2018) Respiratory infections due to Streptococcus pneumoniae and the influenza virus in South Africans undertaking the Hajj. Southern African Journal of Infectious Diseases 0:0, pages 1-5.
Read now
Read now
Mingjuan Yin, Lingfeng Huang, Yan Zhang, Na Yu, Xiaojia Xu, Yaping Liang & Jindong Ni. (2018) Effectiveness and safety of dual influenza and pneumococcal vaccination versus separate administration or no vaccination in older adults: a meta-analysis. Expert Review of Vaccines 17:7, pages 653-663.
Read now
Read now
Yang Wang, Jingxin Li, Yuxiao Wang, Wei Gu & Fengcai Zhu. (2018) Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations. Human Vaccines & Immunotherapeutics 14:4, pages 1003-1012.
Read now
Read now
Angel Vila-Corcoles, Olga Ochoa-Gondar, Imma Hospital, Cinta de Diego, Eva Satué, Jordi Bladé, Xabier Ansa, Jorge A. Guzmán, Elisabet Salsench & Francisca Ramos. (2016) Pneumococcal vaccination coverages among low-, intermediate-, and high-risk adults in Catalonia. Human Vaccines & Immunotherapeutics 12:11, pages 2953-2958.
Read now
Read now
Kena A Swanson, H Josef Schmitt, Kathrin U Jansen & Annaliesa S Anderson. (2015) Adult vaccination. Human Vaccines & Immunotherapeutics 11:1, pages 150-155.
Read now
Read now
Paolo Durando, Roberto Rosselli, Ilaria Cremonesi, Andrea Orsi, Erika Albanese, Ilaria Barberis, Chiara Paganino, Cecilia Trucchi, Mariano Martini, Lorenzo Marensi, Valter Turello, the Ligurian Pneumococcal Study Group, Alessandro Bregante, Roberto Cacciani, Rocco Iudici, Diego La Marca, Leonardo Pedano, Amadio Franco Petrucci, Maria Santolini, Valentina Sbisà & Monica Zacconi. (2015) Safety and tolerability of 13-valent pneumococcal conjugate vaccine in the elderly. Human Vaccines & Immunotherapeutics 11:1, pages 172-177.
Read now
Read now
Yiling Jiang, Aline Gauthier, Sam Keeping & Stuart Carroll. (2014) A public health and budget impact analysis of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK. Expert Review of Pharmacoeconomics & Outcomes Research 14:6, pages 901-911.
Read now
Read now
Yiling Jiang, Aline Gauthier, Sam Keeping & Stuart Carroll. (2014) Cost–effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK. Expert Review of Pharmacoeconomics & Outcomes Research 14:6, pages 913-927.
Read now
Read now
Shijun Liu, Erping Xu, Yan Liu, Yuyang Xu, Jun Wang, Jian Du, Xiaoping Zhang, Xinren Che & Wenwen Gu. (2014) Factors associated with pneumococcal vaccination among an urban elderly population in China. Human Vaccines & Immunotherapeutics 10:10, pages 2994-2999.
Read now
Read now
David S Fedson. (2014) Preventing non bacteremic pneumococcal pneumonia in older adults. Human Vaccines & Immunotherapeutics 10:5, pages 1322-1330.
Read now
Read now
David S Fedson. (2014) Pneumococcal conjugate vaccination for older adults. Human Vaccines & Immunotherapeutics 10:1, pages 47-51.
Read now
Read now
Pawel Grzesiowski, Raquel Aguiar-Ibáñez, Aleksandra Kobryń, Laure Durand & Pierre-Emmanuel Puig. (2012) Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland. Human Vaccines & Immunotherapeutics 8:10, pages 1382-1394.
Read now
Read now
Yiling Jiang, Aline Gauthier, Lieven Annemans, Mark van der Linden, Laurence Nicolas-Spony & Xavier Bresse. (2012) A public health and budget impact analysis of vaccinating at-risk adults and the elderly against pneumococcal diseases in Germany. Expert Review of Pharmacoeconomics & Outcomes Research 12:5, pages 631-643.
Read now
Read now
Yiling Jiang, Aline Gauthier, Lieven Annemans, Mark van der Linden, Laurence Nicolas-Spony & Xavier Bresse. (2012) Cost–effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany. Expert Review of Pharmacoeconomics & Outcomes Research 12:5, pages 645-660.
Read now
Read now
Articles from other publishers (68)
Di PAN, Erik NIELSEN, Samuel CHUNG & Michael S. NIEDERMAN. (2023) Management of pneumonia in the critically ill. Minerva Medica 114:5.
Crossref
Crossref
A. M. Kostinov, A. A. Tarasova & K. V. Mashilov. (2023) Pneumococcal Vaccine in Adults with Bronchopulmonary Pathology: from Prevention to Treatment. Epidemiology and Vaccinal Prevention 22:3, pages 93-99.
Crossref
Crossref
Arne Janssens, Bert Vaes, Chloé Abels, Jonas Crèvecoeur, Pavlos Mamouris, Barbara Merckx, Pieter Libin, Gijs Van Pottelbergh & Thomas Neyens. (2023) Pneumococcal vaccination coverage and adherence to recommended dosing schedules in adults: a repeated cross-sectional study of the INTEGO morbidity registry. BMC Public Health 23:1.
Crossref
Crossref
Manuela Dominique Wennekes, Renske Eilers, Antonella Caputo, Amandine Gagneux-Brunon, Riccardo Gavioli, Francesco Nicoli, Zoltán Vokó, Aura Timen, Amandine Gagneux-Brunon, Anna Czwarno, Antonella Caputo, Atika Abelin, Aura Timen, Cristina Angelin-Duclos, Elisabeth Botelho-Nevers, Florence Baron-Papillon, Francesco Nicoli, Manuela Wennekes, Maria Syrochkina, Mart Stein, Paul Stephane, Renske Eilers, Riccardo Gavioli, Sibilia Quilici, Simon Lewin, Yan Sergerie, Zoltán Vokó, Debbie van Baarle & Jim Janimak. (2022) Focus group study on perceptions and information needs regarding vaccines targeting the older population: a cross-country comparison in four European countries. GeroScience 45:2, pages 871-887.
Crossref
Crossref
Xin Li, Chao Pan, Zhicheng Liu, Peng Sun, Xiaoting Hua, Erling Feng, Yunsong Yu, Jun Wu, Li Zhu & Hengliang Wang. (2021)
Safety and immunogenicity of a new glycoengineered vaccine against
Acinetobacter baumannii
in mice
. Microbial Biotechnology 15:2, pages 703-716.
Crossref
Crossref
Kyra D. Zens, Vasiliki Baroutsou, Jan S. Fehr & Phung Lang. (2022) Pneumococcal Vaccination Coverage and Uptake Among Adults in Switzerland: A Nationwide Cross-Sectional Study of Vaccination Records. Frontiers in Public Health 9.
Crossref
Crossref
Vasilica Ungureanu. (2022) Aspects regarding the etiology of community pneumonia. Medic.ro 3:147, pages 34.
Crossref
Crossref
Yi Hu, Yusi Liu, Yibing Yin & Xuemei Zhang. (2021) Protective efficacy of mucosal and subcutaneous immunization with DnaJ-ΔA146Ply against influenza and Streptococcus pneumoniae co-infection in mice. Microbes and Infection 23:8, pages 104813.
Crossref
Crossref
Davide L. Vetrano, Federico Triolo, Stefania Maggi, Richard Malley, Thomas A. Jackson, Andrea Poscia, Roberto Bernabei, Luigi Ferrucci & Laura Fratiglioni. (2021) Fostering healthy aging: The interdependency of infections, immunity and frailty. Ageing Research Reviews 69, pages 101351.
Crossref
Crossref
Antoni Torres, Catia Cilloniz, Michael S. Niederman, Rosario Menéndez, James D. Chalmers, Richard G. Wunderink & Tom van der Poll. (2021) Pneumonia. Nature Reviews Disease Primers 7:1.
Crossref
Crossref
Saeed Shoar & Daniel M. Musher. (2020) Etiology of community-acquired pneumonia in adults: a systematic review. Pneumonia 12:1.
Crossref
Crossref
Annelies Müller, Anke Salmen, Suzanne Aebi, Linda de Gouveia, Anne von Gottberg & Lucy J. Hathaway. (2020) Pneumococcal serotype determines growth and capsule size in human cerebrospinal fluid. BMC Microbiology 20:1.
Crossref
Crossref
Kang Hao Cheong. (2020) Repurposing Vaccines in the Fight against COVID‐19. BioEssays 42:11, pages 2000234.
Crossref
Crossref
Robert Root‐Bernstein. (2020) Age and Location in Severity of COVID‐19 Pathology: Do Lactoferrin and Pneumococcal Vaccination Explain Low Infant Mortality and Regional Differences?. BioEssays 42:11, pages 2000076.
Crossref
Crossref
Robert Root-Bernstein. (2020) Possible Cross-Reactivity between SARS-CoV-2 Proteins, CRM197 and Proteins in Pneumococcal Vaccines May Protect Against Symptomatic SARS-CoV-2 Disease and Death. Vaccines 8:4, pages 559.
Crossref
Crossref
Gabriela Moreno & Rodolfo Villena. (2020) Vacunas en salud laboral… una oportunidad para prevenir e invertir en salud. Revista Médica Clínica Las Condes 31:3, pages 287-303.
Crossref
Crossref
Christien Rondaan, Victoria Furer, Marloes W Heijstek, Nancy Agmon-Levin, Marc Bijl, Ferdinand C Breedveld, Raffaele D’Amelio, Maxime Dougados, Meliha C Kapetanovic, Jacob M van Laar, Annette Ladefoged de Thurah, Robert Landewé, Anna Molto, Ulf Müller-Ladner, Karen Schreiber, Leo Smolar, Jim Walker, Klaus Warnatz, Nico M Wulffraat, Sander van Assen & Ori Elkayam. (2019) Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations. RMD Open 5:2, pages e001035.
Crossref
Crossref
Mark van der Linden, Matthias Imöhl & Stephanie Perniciaro. (2019) Limited indirect effects of an infant pneumococcal vaccination program in an aging population. PLOS ONE 14:8, pages e0220453.
Crossref
Crossref
Angel Vila-Córcoles, Olga Ochoa-Gondar, Cinta de Diego, Eva Satué, Angel Vila-Rovira & Maria Aragón. (2019) Pneumococcal vaccination coverages by age, sex and specific underlying risk conditions among middle-aged and older adults in Catalonia, Spain, 2017. Eurosurveillance 24:29.
Crossref
Crossref
Andreia N. Horácio, Catarina Silva-Costa, Elísia Lopes, Mário Ramirez & José Melo-Cristino. (2018) Conjugate vaccine serotypes persist as major causes of non-invasive pneumococcal pneumonia in Portugal despite declines in serotypes 3 and 19A (2012-2015). PLOS ONE 13:11, pages e0206912.
Crossref
Crossref
Susan J. Ermlich, Charles P. Andrews, Steven Folkerth, Richard Rupp, David Greenberg, Richard D. McFetridge, Jonathan Hartzel, Rocio D. Marchese, Jon E. Stek, Chitrananda Abeygunawardana & Luwy K. Musey. (2018) Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age. Vaccine 36:45, pages 6875-6882.
Crossref
Crossref
Céline Maréchal, Himal Lal, Airi Poder, Murdo Ferguson, Igwebuike Enweonye, Thomas C Heineman, Caroline Hervé, Paul Rheault, Jaak Talli, Dominique Wauters & Lidia Oostvogels. (2018) Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial. Vaccine 36:29, pages 4278-4286.
Crossref
Crossref
Josef Singer, Christoph Testori, Peter Schellongowski, Ammon Handisurya, Catharina Müller, Eva-Maria Reitter, Wolfgang Graninger, Paul Knöbl, Thomas Staudinger, Stefan Winkler & Florian Thalhammer. (2017) A case report of septic shock syndrome caused by S. pneumoniae in an immunocompromised patient despite of vaccination. BMC Infectious Diseases 17:1.
Crossref
Crossref
Heather L. Sings. (2017) Pneumococcal conjugate vaccine use in adults – Addressing an unmet medical need for non-bacteremic pneumococcal pneumonia. Vaccine 35:40, pages 5406-5417.
Crossref
Crossref
Yufeng Su, Dagen Li, Yan Xing, Hong Wang, Jian Wang, Jun Yuan, Xiaofang Wang, Fang Cui, Yibing Yin & Xuemei Zhang. (2017) Subcutaneous Immunization with Fusion Protein DnaJ-ΔA146Ply without Additional Adjuvants Induces both Humoral and Cellular Immunity against Pneumococcal Infection Partially Depending on TLR4. Frontiers in Immunology 8.
Crossref
Crossref
Yu Bin Seo, Won Suk Choi, Jacob Lee, Joon Young Song, Hee Jin Cheong & Woo Joo Kim. (2017) Comparison of immunogenicity and safety of an influenza vaccine administered concomitantly with a 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide pneumococcal vaccine in the elderly. Clinical and Experimental Vaccine Research 6:1, pages 38.
Crossref
Crossref
Joon Young Song, Hee Jin Cheong, Hak Jun Hyun, Yu Bin Seo, Jacob Lee, Seong-Heon Wie, Min Joo Choi, Won Suk Choi, Ji Yun Noh, Jae Won Yun, Jin Gu Yun & Woo Joo Kim. (2017) Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine and an MF59-adjuvanted influenza vaccine after concomitant vaccination in ⩾60-year-old adults. Vaccine 35:2, pages 313-320.
Crossref
Crossref
Anne L. Wyllie, Lidewij W. Rümke, Kayleigh Arp, Astrid A. T. M. Bosch, Jacob P. Bruin, Nynke Y. Rots, Alienke J. Wijmenga-Monsuur, Elisabeth A. M. Sanders & Krzysztof Trzciński. (2016) Molecular surveillance on Streptococcus pneumoniae carriage in non-elderly adults; little evidence for pneumococcal circulation independent from the reservoir in children. Scientific Reports 6:1.
Crossref
Crossref
Daijun Zhao, Ruoyan Gai Tobe, Min Cui, Jinchun He & Bin Wu. (2016) Cost-effectiveness of a 23-valent pneumococcal polysaccharide vaccine immunization programme for the elderly in Shanghai, China. Vaccine 34:50, pages 6158-6165.
Crossref
Crossref
M. Guimarães, A. Bugalho, A.S. Oliveira, J. Moita & A. Marques. (2016) COPD control: Can a consensus be found?. Revista Portuguesa de Pneumologia (English Edition) 22:3, pages 167-176.
Crossref
Crossref
Carmen Lucía Contreras, Jennifer R. Verani, María Renee Lopez, Antonio Paredes, Chris Bernart, Fabiola Moscoso, Aleida Roldan, Wences Arvelo, Kim A. Lindblade & John P. McCracken. (2015) Incidence of Hospitalized Pneumococcal Pneumonia among Adults in Guatemala, 2008-2012. PLOS ONE 10:10, pages e0140939.
Crossref
Crossref
Selya-Hammer Carl, Fleming Douglas, Jiang Yiling, Durnall Hayley, Keeping Sam & Carroll Stuart. (2015) Co-Administration of PPV23 and Influenza Vaccines in England and Wales: A Study Based on the Royal College of General Practitioners Sentinel Surveillance Network. Journal of Vaccines and Immunology 1:1, pages 043-049.
Crossref
Crossref
K.A. Bryant, R. Frenck, A. Gurtman, J. Rubino, J. Treanor, A. Thompson, T.R. Jones, V. Sundaraiyer, L.M. Baxter, W.C. Gruber, E.A. Emini, D.A. Scott & B. Schmoele-Thoma. (2015) Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18–49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine. Vaccine 33:43, pages 5854-5860.
Crossref
Crossref
Joon Young Song, Hee Jin Cheong, T.F. Tsai, Hyun-ah Chang, Min Joo Choi, Ji Ho Jeon, Seong Hee Kang, Eun Ju Jeong, Ji Yun Noh & Woo Joo Kim. (2015) Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults. Vaccine 33:36, pages 4647-4652.
Crossref
Crossref
Mark van der Linden, Gerhard Falkenhorst, Stephanie Perniciaro & Matthias Imöhl. (2015) Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany. PLOS ONE 10:7, pages e0131494.
Crossref
Crossref
K. Aaron Geno, Gwendolyn L. Gilbert, Joon Young Song, Ian C. Skovsted, Keith P. Klugman, Christopher Jones, Helle B. Konradsen & Moon H. Nahm. (2015) Pneumococcal Capsules and Their Types: Past, Present, and Future. Clinical Microbiology Reviews 28:3, pages 871-899.
Crossref
Crossref
Susanna Esposito & Nicola Principi. (2015) Pneumococcal vaccines and the prevention of community-acquired pneumonia. Pulmonary Pharmacology & Therapeutics 32, pages 124-129.
Crossref
Crossref
Mario Ramirez. 2015. Molecular Medical Microbiology. Molecular Medical Microbiology
1529
1546
.
C. Forstner & M.W. Pletz. (2014) PneumokokkenimpfungPneumococcal vaccination. Der Pneumologe 11:6, pages 506-515.
Crossref
Crossref
Charles Feldman & Ronald Anderson. (2014) Review: Current and new generation pneumococcal vaccines. Journal of Infection 69:4, pages 309-325.
Crossref
Crossref
Paolo Castiglia. (2014) Recommendations for Pneumococcal Immunization Outside Routine Childhood Immunization Programs in Western Europe. Advances in Therapy 31:10, pages 1011-1044.
Crossref
Crossref
Pierre-Olivier Lang & Richard Aspinall. (2014) Vaccination in the Elderly: What Can Be Recommended?. Drugs & Aging 31:8, pages 581-599.
Crossref
Crossref
Andreia N. Horácio, Joana P. Lopes, Mário Ramirez & José Melo-Cristino. (2014) Non-Invasive Pneumococcal Pneumonia in Portugal—Serotype Distribution and Antimicrobial Resistance. PLoS ONE 9:7, pages e103092.
Crossref
Crossref
Mehdi Mirsaeidi & Dean E. Schraufnagel. (2014) Pneumococcal Vaccines: Understanding Centers for Disease Control and Prevention Recommendations. Annals of the American Thoracic Society 11:6, pages 980-985.
Crossref
Crossref
S. Aliberti, M. Mantero, M. Mirsaeidi & F. Blasi. (2014) The role of vaccination in preventing pneumococcal disease in adults. Clinical Microbiology and Infection 20, pages 52-58.
Crossref
Crossref
John D. Grabenstein & Luwy K. Musey. (2014) Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adults. Vaccine 32:21, pages 2399-2405.
Crossref
Crossref
C. Raina MacIntyre, Iman Ridda, Zhanhai Gao, Aye M. Moa, Peter B. McIntyre, John S. Sullivan, Thomas R. Jones, Andrew Hayen & Richard I. Lindley. (2014) A Randomized Clinical Trial of the Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine Compared to 23-Valent Polysaccharide Vaccine in Frail, Hospitalized Elderly. PLoS ONE 9:4, pages e94578.
Crossref
Crossref
Paola Faverio, Stefano Aliberti, Giuseppe Bellelli, Giulia Suigo, Sara Lonni, Alberto Pesci & Marcos I. Restrepo. (2014) The management of community-acquired pneumonia in the elderly. European Journal of Internal Medicine 25:4, pages 312-319.
Crossref
Crossref
Jieling Chen, Megan A. O’Brien, H. Keri Yang, John D. Grabenstein & Erik J. Dasbach. (2014) Cost-Effectiveness of Pneumococcal Vaccines for Adults in the United States. Advances in Therapy 31:4, pages 392-409.
Crossref
Crossref
J. D. Grabenstein & D. J. Weber. (2013) Pneumococcal Serotype Diversity Among Adults in Various Countries, Influenced by Pediatric Pneumococcal Vaccination Uptake. Clinical Infectious Diseases 58:6, pages 854-864.
Crossref
Crossref
Joon Young Song & Hee Jin Cheong. (2014) Pneumococcal vaccine. Journal of the Korean Medical Association 57:9, pages 780.
Crossref
Crossref
Renske Eilers, Paul FM Krabbe, Ted GA van Essen, Anita Suijkerbuijk, Alies van Lier & Hester E de Melker. (2013) Assessment of vaccine candidates for persons aged 50 and older: a review. BMC Geriatrics 13:1.
Crossref
Crossref
Andreia N. Horácio, Jorge Diamantino-Miranda, Sandra I. Aguiar, Mário Ramirez & José Melo-Cristino. (2013) The Majority of Adult Pneumococcal Invasive Infections in Portugal Are Still Potentially Vaccine Preventable in Spite of Significant Declines of Serotypes 1 and 5. PLoS ONE 8:9, pages e73704.
Crossref
Crossref
M. Paccalin. (2013) Should adult pneumococcal vaccine guidelines be updated throughout Europe?. European Geriatric Medicine 4:4, pages 266-268.
Crossref
Crossref
Pontus Naucler, Jessica Darenberg, Eva Morfeldt, Åke Örtqvist & Birgitta Henriques Normark. (2013) Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia. Thorax 68:6, pages 571-579.
Crossref
Crossref
Catia T. Perciani, Giovana C. Barazzone, Cibelly Goulart, Eneas Carvalho, Joaquin Cabrera-Crespo, Viviane M. Gonçalves, Luciana C. C. Leite & Martha M. Tanizaki. (2013) Conjugation of Polysaccharide 6B from Streptococcus pneumoniae with Pneumococcal Surface Protein A: PspA Conformation and Its Effect on the Immune Response. Clinical and Vaccine Immunology 20:6, pages 858-866.
Crossref
Crossref
Angel Vila-Corcoles & Olga Ochoa-Gondar. (2013) Preventing Pneumococcal Disease in the Elderly. Drugs & Aging 30:5, pages 263-276.
Crossref
Crossref
Hartmut Lode, Endre Ludwig & George Kassianos. (2013) Pneumococcal Infection — Low Awareness as a Potential Barrier to Vaccination: Results of a European Survey. Advances in Therapy 30:4, pages 387-405.
Crossref
Crossref
Thomas A. Russo, Janet M. Beanan, Ruth Olson, Ulrike MacDonald, Andrew D. Cox, Frank St. Michael, Evgeny V. Vinogradov, Brad Spellberg, Nicole R. Luke-Marshall & Anthony A. Campagnari. (2013) The K1 Capsular Polysaccharide from Acinetobacter baumannii Is a Potential Therapeutic Target via Passive Immunization. Infection and Immunity 81:3, pages 915-922.
Crossref
Crossref
Olga H. Torres, Eva Gil, Cristina Pacho & Domingo Ruiz. (2013) Actualización de la neumonía en el anciano. Revista Española de Geriatría y Gerontología 48:2, pages 72-78.
Crossref
Crossref
Ursula Wiedermann. 2013. Travel Medicine. Travel Medicine
77
86
.
J. D. Grabenstein. (2012) Reply to Truck et al. Clinical Infectious Diseases 55:11, pages 1579-1581.
Crossref
Crossref
L.F. Pittet & K.M. Posfay-Barbe. (2012) Pneumococcal vaccines for children: a global public health priority. Clinical Microbiology and Infection 18, pages 25-36.
Crossref
Crossref
J. D. Grabenstein. (2012) Effectiveness and Serotype Coverage: Key Criteria for Pneumococcal Vaccines for Adults. Clinical Infectious Diseases 55:2, pages 255-258.
Crossref
Crossref
J. Gaillat. (2012) Les vaccins antipneumococciques chez l’adulte : où en sommes-nous ?. Journal des Anti-infectieux 14:2, pages 96-103.
Crossref
Crossref
Belma Ljutic, Martina Ochs, Benjamin Messham, Marin Ming, Annie Dookie, Kevin Harper & Salvador F. Ausar. (2012) Formulation, stability and immunogenicity of a trivalent pneumococcal protein vaccine formulated with aluminum salt adjuvants. Vaccine 30:19, pages 2981-2988.
Crossref
Crossref
Andreia N. Horácio, Jorge Diamantino-Miranda, Sandra I. Aguiar, Mário Ramirez & José Melo-Cristino. (2012) Serotype changes in adult invasive pneumococcal infections in Portugal did not reduce the high fraction of potentially vaccine preventable infections. Vaccine 30:2, pages 218-224.
Crossref
Crossref
John D. Grabenstein & Susan B. Manoff. (2011) Pneumococcal vaccines in adults: Assessing the evolving evidence. Vaccine 29:37, pages 6149-6154.
Crossref
Crossref